The FDA has approved Samsung Bioepis’ Ontruzant (trastuzumab-dttb), a biosimilar trastuzumab referencing Herceptin, for the treatment of HER2-positive breast cancer and HER2 overexpressing gastric cancer.
Kelly Davio contributed to this article.
The FDA has approved Samsung Bioepis’ Ontruzant (trastuzumab-dttb), a biosimilar trastuzumab referencing Herceptin, for the treatment of HER2-positive breast cancer and HER2 overexpressing gastric cancer.
The drug was first approved by the European Medicines Agency in November 2017, making it the first biosimilar trastuzumab to be approved in the European Union. Since the approval, Europe has also seen the entry of 3 additional versions of biosimilar trastuzumab, Herzuma, Kanjinti, and Ogivri.
Ontruzant will now compete in the United States with the reference product, Herceptin, which in the third quarter of 2018 had earned developer Roche an estimated $5,332,998 globally. The newly approved biosimilar will also eventually compete with 2 prior FDA approved biosimilars: Ogivri, developed by Mylan and Biocon, and Herzuma, developed by Celltrion and Teva. To date, no trastuzumab biosimilars have launched in the United States, and Roche has reportedly reached an undisclosed agreement with Mylan concerning the launch of Ogivri in the United States.
Under a prior agreement, Ontruzant will be commercialized in the United States by Merck.
Samsung Bioepis recently revealed safety and efficacy results for the biosimilar at 1 year. The results, presented in an abstract at the 2018 San Antonio Breast Cancer Symposium, held in San Antonio, Texas, from December 4 to 8, 2018, reported on a study of patients with HER2-positive early breast cancer or locally advanced breast cancer who were randomized to receive either the biosimilar or its reference concurrently with chemotherapy.
Patients underwent surgery, then received treatment with either SB3 or its reference. Afterward, 367 patients—181 of whom had been treated with the reference trastuzumab and 186 of whom had been treated with the biosimilar—were enrolled.
Within the group of patients treated with the reference, 126 patients had been exposed to lots of trastuzumab, with expiry dates from August 2018 to December 2019, that had a lower antibody-dependent cell-mediated cytotoxicity (ADCC) than other lots of the reference product. The remaining 55 patients given the reference therapy were unexposed to these lots. After 30.1 months of treatment with the biosimilar and 30.2 months of treatment with the reference, there was no statistically significant difference in event-free survival between the biosimilar arm (96.7%) and the patients who were unexposed to the lower-ADCC activity lots of the reference (98.2%) (hazard ratio [HR], 1.19; 95% CI, 0.23-6.18; P = .8376).
Reference
Pegram MD, Pivot X, Cortes J, et al. Event-free survival by ADCC status from a follow-up study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab for HER2 positive breast cancer in neoadjuvant setting. Presented at the 2018 San Antonio Breast Cancer Symposium, December 408, 2018; San Antonio, Texas. Abstract P6-17-09. https://www.sabcs.org/Program/Poster-Sessions/Poster-Session-6?rel=0" .
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.